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ABSTRACT: Microcrystals of piroxicam (PRX) monohydrate
with a narrow size distribution were prepared from acetone/
PRX solutions by antisolvent crystallization via metallic
membranes with ordered pore arrays. Crystallization was
achieved by controlled addition of the feed solution through
the membrane pores into a well-stirred antisolvent. A complete
transformation of an anhydrous form I into a monohydrate
form of PRX was confirmed by Raman spectroscopy and
differential scanning calorimetry. The size of the crystals was
7−34 μm and was controlled by the PRX concentration in the
feed solution (15−25 g L−1), antisolvent/solvent volume ratio
(5−30), and type of antisolvent (Milli-Q water or 0.1−0.5 wt
% aqueous solutions of hydroxypropyl methyl cellulose
(HPMC), poly(vinyl alcohol) or Pluronic P-123). The smallest crystals were obtained by injecting 25 g L−1 PRX solution
through a stainless-steel membrane with a pore size of 10 μm into a 0.06 wt % HPMC solution stirred at 1500 rpm using an
antisolvent/solvent ratio of 20. HPMC provided better steric stabilization of microcrystals against agglomeration than poly(vinyl
alcohol) and Pluronic P-123, due to hydrogen bonding interactions with PRX and water. A continuous production of large PRX
monohydrate microcrystals with a volume-weighted mean diameter above 75 μm was achieved in a continuous stirred membrane
crystallizer. Rapid pouring of Milli-Q water into the feed solution resulted in a mixture of highly polydispersed prism-shaped and
needle-shaped crystals.
1. INTRODUCTION
Low aqueous solubility of active pharmaceutical ingredients
(APIs) is a major problem in the design of pharmaceutical
dosage forms.1−3 Over 60% of APIs fall under BCS Class II
(low solubility and high permeability) or Class IV (low
solubility and low permeability). As such, they suffer from low
bioavailability and incomplete/erratic adsorption.4,5 A low drug
solubility leads to a low concentration gradient in the liquid
medium, resulting in a low dissolution rate of the drug,
according to the Noyes−Whitney equation. Drug bioavailability
can be improved by increasing the surface area of a drug
substance, which depends on its particle size.2,6
The surface area of drug substances can be increased by
mechanical milling,7 high pressure homogenization,8 and spray
drying.9 However, these techniques require high energy inputs
and expensive equipment, and often lead to a broad particle size
distribution, thermal degradation, heterogeneous particle
shapes, and poor batch-to-batch reproducibility.3,4,10 Anti-
solvent precipitation/crystallization is an alternative approach
to prepare fine drug particles.11,12 The technique is simple and
does not require elevated temperatures, high energy inputs, and
Class 1 solvents.13−17 It has been used to prepare ultrafine
powders and micro-/nanodispersions of many APIs, including
budesonide,18 danazol,19 beclomethasone dipropionate,20 gri-
seofulvin and fenofibrate,21 salbutamol sulfate,22 predniso-
lone,23 atorvastatin,24 L-glutamic acid,25 and paracetamol.26
Piroxicam (PRX, 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-
benzothiazine-3-carboxamide-1,1-dioxide) is a nonsteroidal
anti-inflammatory drug, which is mainly used in the treatment
of rheumatic diseases.27 PRX is a BCS Class II drug with a high
intestinal membrane permeability, but low water solubility.28
PRX has three anhydrous white polymorphs, forms I, II, and
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III, whose crystal structure was confirmed29 and one yellow
monohydrate form. Anhydrous forms contain neutral PRX
molecules in their crystal lattices, whereas the monohydrate
form contains zwitterionic piroxicam molecules. The mono-
hydrate form converts to anhydrous forms by heating at high
temperatures, while the anhydrous forms revert to the
monohydrate form in aqueous solutions. Since different
polymorphs of PRX display different pharmacokinetic and
pharmacodynamic properties,30 a crystallization process must
be carried out in such a way to gain control over the
polymorphic form of PRX obtained.
Coupling membrane permeation with antisolvent crystal-
lization is a promising strategy to precisely control the level of
supersaturation owing to controllable mass transfer rates across
the membrane.31−33 The most common approach is to
combine membrane distillation with antisolvent crystalliza-
tion.34,35 In this approach, the membrane is hydrophobic and
the transmembrane pressure difference is sufficiently small such
that the liquid cannot penetrate the pores, so that the transfer
of solvent and antisolvent between the two contacting liquids is
carried out in vapor phase across the air-filled pores. Since the
temperature and/or concentration difference must be main-
tained across the membrane to create a vapor pressure gradient,
the process is complicated, slow, and associated with relatively
high energy consumption.
An alternative approach suggested by Bakker et al.36 is to
force a crystallizing solution through the membrane directly
into the antisolvent by overcoming the capillary pressure in the
pores. In this process, the wetting properties of the membrane
are not critically important, except for the fact that hydrophilic
membranes can achieve higher fluxes of aqueous solutions.35 By
using the membrane as a precision dosing device, efficient
micromixing of the feed solution and the antisolvent can be
achieved. The membrane pores act as numerous micron-sized
feed introduction points, which results in uniform super-
saturation along the membrane. Compared to evaporative
membrane crystallization, the process is much faster and less
energy demanding, since it does not require any heat transfer.
Fine tuning of the mixing process can be achieved by proper
membrane selection and adjusting the level of shear stress on
the membrane surface by controlled cross-flow,37 stirring,16
pulsed cross-flow,38 and low frequency membrane vibration39
or rotation.40
In this work, microcrystals of PRX monohydrate have been
prepared for the first time using antisolvent membrane
crystallization process. The feed solution was dispersed into
antisolvent using two different microengineered membranes,
stainless steel membrane with laser drilled pores and electro-
formed nickel membrane. Metallic membranes with evenly
spaced uniform pores have extensively been used for
dispersion.16,41−43 Because of their isoporous structure, small
thickness, and straight and nontortuous pores, they offer
uniform micromixing, low resistance to flow, and suppression
of internal fouling. The effect of pore morphology and spatial
arrangement of the pores on the rate of micromixing was
investigated elsewhere.17 The main objective of this work was
to elucidate the effects of formulation factors, operating
conditions, and mode of system operation on the morphology,
polymorphic form, and size distribution of the produced PRX
microcrystals.
2. MATERIALS AND METHODS
2.1. Chemicals. Piroxicam (PRX) (99% purity, anhydrous) was
obtained from Hangzhou Hyper Chemicals Limited (Zhejiang,
China). Acetone (purity ≥99.98%) supplied from Fisher Scientific,
UK was used as a solvent for PRX. Poly(vinyl alcohol) (PVA, Mw =
13000−23000 g mol−1, 87−89% hydrolyzed), a symmetric triblock
copolymer Pluronic P-123 (Mn ≈ 5800), and hydroxylpropyl
methylcellulose (HPMC, Mw ≈ 10,000) were purchased from
Sigma-Aldrich, UK, and used as surfactants. The antisolvent was
Milli-Q water or aqueous surfactant solutions. The feed solution was a
PRX/acetone mixture containing 15−25 g L−1 of PRX. At the lower
PRX concentration (<15 g/L), the solution could not easily nucleate,
Figure 1. (a) Batch membrane dispersion system consisting of (i) stirred cell and (ii) ringed stainless-steel (SS) membrane with 10-μm laser drilled
pores (Dm = 3.3 cm, r1 = 0.9 cm, r2 = 1.3 cm); (b) continuous membrane dispersion system composed of (i) continuous flow stirred cell and (ii)
nickel membrane with 40-μm pores (Dm = 3.3 cm). Microcrystals were formed in the cell above the membrane surface, as shown in inset panel a
(iii).
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and the maximum solubility of PRX in acetone at the room
temperature was about 25 g/L.
2.2. Dispersion Cell. The experiments in Sections 3.1−3.6 were
carried out using a batch membrane system (Figure 1a) consisting of a
stirred cell and a ringed stainless-steel (SS) membrane, both supplied
by Micropore Technologies Ltd. (Redcar, UK). The stirring blade was
fixed in the cell 2.4 cm above the membrane surface. The SS
membrane had about 6900 cylindrical pores with a diameter of 10 μm
fabricated by laser ablation. The pores were arranged in a square
lattice, 200 μm spaced apart, and occupied a circular ring region on the
membrane surface with an area of Ar = 2.76 cm
2 (Figure 1a(ii)). A
nickel membrane with an effective cross-sectional surface area of A =
8.55 cm2 was used in a continuous system shown in Figure 1b. The
nickel membrane consisted of ∼24 690 pores with a diameter of 40 μm
fabricated by electroforming. The pores were arranged over the whole
membrane surface in a hexagonal lattice and spaced apart at the
distance of 200 μm (Figure 1b(ii)). The whole membrane was less
prone to fouling in continuous operation, because it was operated at
the smaller flux than the ringed membrane.
2.3. Experimental Setup. 2.3.1. Batch System. The cell was filled
with 15−90 mL of the antisolvent. The stirrer speed was adjusted at
1,500 rpm, which generated a peak shear stress of 17.5 Pa at the radial
distance of r = 1.1 cm from the center of the membrane. The feed
solution (3 mL of 15−25 g L−1 PRX in acetone) was injected through
the membrane at the flow rate of Q = 18 mL min−1 using a syringe
pump (11 Elite, Harvard Apparatus, UK). The final antisolvent/
solvent volume ratio was 5−30, depending on the volume of the
antisolvent used. The flux through the ringed membrane, Jr = Qor/Ar,
was 4,000 L m−2 h−1. The antisolvent turned to a bumblebee yellow
color due to solvent-antisolvent displacement, resulting in the creation
of supersaturation that was relieved by crystal nucleation and growth
(Figure 1a (iii)). After organic phase injection, the suspension of
microcrystals was stirred in the cell for additional 2 min and acetone
was then allowed to completely evaporate. Each experiment was
repeated three times. No significant difference in CSD was detected
before and after solvent evaporation, as described in Figure S1
(Supporting Information).
2.3.2. Continuous System. This system shown in Figure 2b was
provided by Micropore Technologies Ltd. (Redcar, UK). The feed
solution with 15 g L−1 PRX was continuously injected through the
membrane at 18 mL min−1 using a peristaltic pump (Masterflex L/S
7544-06 drive, Cole-Parmer, IL). Milli-Q water was continuously
supplied to the cell chamber at 90 mL min−1 using a Watson Marlow
503U peristaltic pump and stirred at 1500 rpm. Therefore, the flow
rate ratio, Qaq/Qor was 5 and the flux through the membrane, J = Qor/
A, was 1260 L m−2 h−1. The product suspension was discharged from
the cell by hydrostatic head difference between the liquid level in the
cell and the end of the outlet hose. The liquid level was regulated with
a pinch valve installed in the outlet hose, which ensured a constant
liquid volume in the cell of 100 mL. The samples of the product
stream were collected regularly over 15 min and analyzed.
The used membrane was cleaned by sonication in acetone for 30
min, according to the procedure described elsewhere.16
2.4. Characterization Techniques. 2.4.1. Particle Size Distribu-
tion. The crystal size distribution (CSD) was measured by laser
diffraction using a Malvern Mastersizer 2000 (Worcestershire, UK). A
saturated aqueous solution of piroxicam monohydrate was used as a
dispersant. The relative volume, Vi, of the particles in different size
classes i, whose mean diameter di ranged from 0.01 to 3500 μm, was
used to calculate the volume-weighted mean diameter, d[4,3]:
= ∑
∑
d
Vd
V
[4,3] i i
i (1)
The size uniformity of the crystals was estimated using span of a
CSD:44
= −d v d v
d v
span
[ ( , 0.9) ( , 0.1)]
( , 0.5) (2)
where d (v, 0.1), d (v, 0.5), and d (v, 0.9) are the particle diameters at
10 vol %, 50 vol %, and 90 vol % of the cumulative distribution.
2.4.2. Raman Microscopy. The polymorphic form of PRX crystals
was determined using a Thermo Scientific DXR Raman microscope
with a 780 nm laser. Each spectrum was acquired using a 10×
Figure 2. Effect of content of PRX in the feed solution on (a) the mean diameter; and (b) the size distribution of the microcrystals. The optical
micrographs of PRX microcrystals produced at the PRX content of (c) 15 g L−1; (d) 25 g L−1. Vaq/Vor = 10, ringed stainless-steel membrane, no
surfactant was added.
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Olympus objective lens by averaging 10 scans, collected within 10 s
each.
2.4.3. Differential Scanning Calorimetry (DSC) and Scanning
Electron Microscopy (SEM). DSC was carried out using a TA 2910
instrument to validate the results obtained by Raman spectroscopy.
The crystals were isolated from the mother liquor by centrifuging and
freeze-drying (Edwards, type EF4Modulyo freeze-dryer). A 5−10 mg
of the sample (freeze-dried crystals or raw PRX) was weighed into an
aluminum pan, then hermetically sealed and heated to 350 °C at a scan
rate of 10 °C min−1. A second empty pan was used as a reference. A
purge gas was dry nitrogen at 60 mL min−1. Each measurement was
repeated three times. SEM three-dimensional (3D) images of PRX
microcrystals were acquired using a Hitachi model TM3030 benchtop
SEM according to the procedure described by Othman at al.16
3. RESULTS AND DISCUSSION
3.1. Effect of the PRX Concentration in the Feed
Solution. The effect of PRX concentration in the feed solution
on the average size of the microcrystals is shown in Figure 2a.
The d[4,3] value decreased with an increase in PRX
concentration from 35 ± 1.0 μm at 15 g L−1 to 24 ± 1.5 μm
at 25 g L−1.
In the absence of attrition and agglomeration, the mean
crystal size depends on the interplay between nucleation and
growth. The rate of crystal growth is G = Kg(CPRX − CPRX*)g,
where Kg is the growth constant, CPRX and CPRX* are the bulk
concentration and solubility of PRX, respectively, and g is 1−2
for organic solutes. The rate of primary nucleation is B =
Kb(CPRX − CPRX*)b, where Kb is the nucleation constant, and b
is 5−10. The promotion of crystal growth over nucleation leads
to fewer and larger crystals. Since b ≫ g, crystal growth is
favored at lower supersaturations and vice versa.19,45,46 Lower
supersaturation was achieved using lower concentration of PRX
in the feed solution. However, the rate of nucleation does not
depend only on the degree of supersaturation, but also on the
concentration of crystals in the cell, i.e., crystal−crystal
collisions, which can promote secondary nucleation (“contact
secondary nucleation”).
The CSD data shown in Figure 2b are consistent with the
above discussion. The minimum crystal size was achieved at 25
g L−1 PRX, due to higher supersaturation and higher
concentration of crystals in suspension, resulting in more
pronounced primary and secondary nucleation. The similar
behavior was reported in conventional antisolvent crystalliza-
tion of drugs such as roxithromycin,47 megestrol acetate,48 and
beclomethasone dipropionate.20
The CSD data are confirmed by optical microscopy (Figure
2c−d) with the larger crystals obtained at the smaller PRX
concentration. However, crystal aggregation was more
pronounced at the higher PRX concentration in the feed
solution, due to the higher concentration of crystals in
suspension and the absence of surfactant in the aqueous phase.
3.2. Effect of Stabilizer. In this section, aqueous solutions
of PVA, P-123, and HPMC of different concentrations were
used as the antisolvent phase. The PRX content in the feed
solution was 25 g L−1 and the antisolvent/solvent volume ratio
was 10. The effect of surfactant concentration on d[4,3] for
three different surfactants is shown in Figure 3a. When pure
water was used as the antisolvent, d[4,3] was 24.0 ± 1.5 μm.
Crystallization kinetics and crystal habit can be greatly
influenced by the adsorption of surfactants onto crystalline
faces. At very low concentrations, surfactants have the ability to
decrease the interfacial tension at a crystal phase/liquid
interface, γSL, thus lowering the height of the free energy
barrier for nucleation, which is given by ΔG* = 16πγSL3v2/3(kT
ln S)2, where v is the volume of a solute molecule in the crystal,
k is the Boltzmann’s constant, T is the absolute temperature,
and S is the supersaturation ratio. Therefore, ΔG* is
proportional to the third power of γSL, and any decrease in
γSL will strongly reduce ΔG* and increase the rate of
nucleation. However, above the surfactant critical micelle
concentration (CMC), γSL is no longer affected by the
surfactant concentration, but nuclei of hydrophobic drugs can
be solubilized inside hydrophobic micellar cores, which can
inhibit their growth. Also, surfactants can inhibit the rate of
mass transfer across the interface by increasing the solution
viscosity or interacting with solute molecules in the solution,
e.g., through hydrogen bonding. Surfactant molecules can also
selectively adsorb onto one or more crystal faces and retard the
growth of the crystal in that direction, thus affecting the final
crystal shape.49−51 Finally, surfactants can prevent agglomer-
ation of small crystallites into large secondary assemblies by
providing steric hindrance.52 Because of complexity and
multiplicity of possible effects, no generalization can be made
as to the effect of surfactants on the nucleation and growth
kinetics of an arbitrary system.
The d[4,3] values for PVA and P-123 in Figure 3a have
inconclusive trends, revealing a complex interplay of different
mechanisms of nucleation inhibition/promotion in the
presence of these surfactants. Over the concentration range
of 0.1−0.5 wt %, the smallest d[4,3] value of 18 μm was
achieved with 0.1 wt % HPMC. To find the optimum HPMC
concentration, additional experiments have been carried out in
the range of 0.03−0.1 wt %, as shown in Figure 3b. The
smallest crystals with a d[4,3] value of 13 μm were achieved at
0.06 wt % HPMC. A decrease in d[4,3] on increasing the
Figure 3. Effect of surfactant concentration in the aqueous phase on
the volume-weighted mean diameter of the microcrystals for (a) P-
123, PVA, and HPMC at 0.1, 0.25, and 0.5 wt %; (b) HPMC at 0.03−
0.5 wt %. The concentration of PRX in the organic phase = 25 g L−1,
Vaq/Vor = 10, ringed SS membrane.
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HPMC concentration from 0.03 to 0.06 wt % can be explained
by lowering the thermodynamic barrier for nucleation, due to a
decrease in γSL,
53 which increases the nucleation rate, ultimately
resulting in smaller crystals. The maximum in the nucleation
rate occurs close to the CMC of HPMC. Once the maximum
degree of adsorption has been reached, further addition of
HPMC will result in the formation of micelles in solution,
without any significant change in γSL. An increase in d[4,3]
from 0.03 wt % to 0.5 wt % HPMC was due to increased
solution viscosity and hydrogen bonding interactions between
HPMC and water or drug molecules. The viscosity of 0.5 wt %
HPMC solution is 2.3 times higher than the viscosity of pure
water.54 The nucleation rate is directly proportional to the
jump frequency of growth units, Γ, from one site to another: Γ
= kT/(3πλ3η), where λ is the diameter of the growth units.
Therefore, Γ is inversely proportional to the viscosity of the
solution, η. A higher solution viscosity also leads to a higher
rate of solvent interdiffusion,55 which can have a strong impact
on the supersaturation generated. Typically, lower rates of
counter-diffusion of solvent and antisolvent lead to lower
supersaturations.
At higher concentrations, HPMC strongly inhibits the
formation of PRX monohydrate nuclei. It can be explained
by HPMC molecules forming hydrogen bonds with water,
which can immobilize water molecules and hinder their
incorporation into the crystal lattice.26,56,57 Similar behavior
was observed by Tian et al.,58 who found that the phase
transformation of anhydrous carbamazepine polymorphic forms
I and III to the dihydrate was inhibited in aqueous HPMC
solutions. In addition, HPMC can form hydrogen bonds with
PRX via OH groups in HPMC and PRX molecules.
Figure 4 shows the size distribution curves and optical
micrographs of the microcrystals stabilized by P-123, PVA, and
HPMC, for three different surfactant concentrations (0.1, 0.25,
and 0.5 wt %). From the micrographs, the smallest micro-
crystals were produced with 0.1 wt % HPMC, which agrees
with the results shown in Figure 3a.
The most uniform crystals were obtained for the highest
concentration of each surfactant. The most severe agglomer-
ation was observed with P-123 (Figure 4a). Agglomeration
occurs when two or more crystals in the suspension collide and
stay in contact long enough for the growth of an agglomerative
bond. The variations in the structure of the adsorbed surfactant
layer and steric hindrance effects lead to considerable
differences in the forces required for the crystal faces to
come into contact, as well as in the growth rate of the
agglomerative bond and its subsequent strength.59 The highest
stability against agglomeration was observed for HPMC (Figure
4c), due to high steric stabilization exerted by this surfactant.
HPMC was observed to reduce sticking of cefuroxime axetil
crystals to stirrer blades due to its high affinity toward newly
formed crystal surfaces.60 The optimal HPMC concentration
for stabilizing microcrystals of cefuroxime axetil was found to be
0.1% (w/v),60 while in this study the optimal HPMC
concentration for stabilizing microcrystals of PRX monohydrate
was 0.06 wt %. The adsorption of surfactants can be surface-
specific or nonspecific. In the case of surface-specific adsorption
of surfactants onto the crystal surface, the surfactant molecules
will selectively adsorb onto a crystal face and retard the growth
of the crystal in that direction, thereby changing the crystal
shape.61 In this study, prism-shaped microcrystals were
obtained in the presence of all surfactants, as well as in Milli-
Q water, meaning that all surfactants adsorbed on all faces
unselectively. Typically, low molecular weight surfactants
adsorb on specific crystal surfaces, whereas surfactants with
larger molecules, like those used in this study, are nonspecific
Figure 4. Size distribution and optical micrographs of the microcrystals stabilized with different surfactants: (a) 0.1−0.5 wt % P-123; (b) 0.1−0.5 wt
% PVA; and (c) 0.1−0.5 wt % HPMC. The concentration of PRX in organic phase = 25 g L−1, Vaq/Vor = 10, ringed SS membrane.
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and hinder the approach of growth units equally on all
surfaces.61
3.3. Effect of Antisolvent/Solvent Ratio. The effect of
antisolvent/solvent ratio was investigated by injecting 3 mL of
the feed solution containing 25 g L−1 PRX into 15, 30, 45, 60,
and 90 mL of 0.06% (w/w) HPMC solution agitated at 1,500
rpm to achieve a Vaq/Vor value of 5, 10, 15, 20, and 30,
respectively. As shown in Figures 5 and 6, d[4,3] was reduced
from 21.2 to 8.4 μm when Vaq/Vor increased from 5 to 20, and
then showed an increase on a further increase in Vaq/Vor from
20 to 30.
Fewer agglomerates were formed in more diluted suspen-
sions (Figure 5c,d), because agglomerates can only form when
small crystallites collide with each other and the collision
frequency of crystallites is proportional to the square of their
number density. Also, a greater volume of antisolvent led to
higher solvent dilution after mixing; the final acetone
concentration was 16.7 vol % at Vaq/Vor = 5 and only 4.8 vol
% at Vaq/Vor = 20, which led to lower solubility, CPRX*, and
higher supersaturation, CPRX − CPRX*, of PRX at Vaq/Vor = 20.
During subsequent crystal growth, the higher antisolvent
volume increases the diffusion path length of growth units,
and diffusion may become the limiting step for the growth of
nuclei.62,63 In addition, the critical nucleus size is smaller at
higher supersaturation.64
A significant increase in d[4,3] from 8.4 to 14.8 μm was
observed with a further increase in Vaq/Vor from 20 to 30
(Figure 6), probably due to suppressed secondary nucleation.
Contact secondary nucleation is a significant additional source
of small nuclei.65 Contact nucleation is triggered by contacts of
existing parent crystals with the stirrer paddles, the vessel walls,
and other crystals. Although the exact mechanism is still
debatable, it is believed that contact nucleation originates from
microattrition at the surface of a parent crystal or displacement
of the semiordered clusters of solute molecules present at the
mother liquor/crystal interface.66 Larger crystals at Vaq/Vor = 30
were formed due to lower frequency of crystal−impeller and
crystal−crystal contacts at higher dilution factor. Therefore, at
low volume ratios (5−10), nucleation kinetics was limited by
thermodynamic factors (low supersaturation ratio), while at
high volume ratios (>20), the nucleation rate was limited by
mechanistic factors (low collision frequency of crystals).
Optical micrographs in Figure 5 are in good correlation with
the results in Figure 6, showing that the crystal size decreases
with a volume ratio up to Vaq/Vor = 20 and then increases up to
Vaq/Vor = 30.
3.4. Effect of Membrane Cleaning Procedure. The role
of the membrane cleaning was to ensure that the pores are not
blocked by the deposited crystals and that the feed solution can
penetrate uniformly into the aqueous phase. The membrane
cleaning procedure was optimized in our previous study and
verified by contact angle measurements.16 No difference in
CSD was found in repeated experiments with clean membrane,
Figure 5.Microscopic images of microcrystals produced at Vaq/Vor of (a) 5; (b) 10; (c) 20; and (d) 30. The PRX content in the organic phase = 25 g
L−1, the HPMC concentration in the aqueous phase = 0.06 wt %, ringed SS membrane.
Figure 6. Average size of PRX monohydrate microcrystals as a
function of volume ratio. The PRX content in the feed solution = 25 g
L−1, the HPMC concentration in the aqueous phase = 0.06 wt %,
ringed SS membrane.
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as shown in Figure S2 (Supporting Information), which means
that the cleaning procedure was appropriate. After cleaning, no
clogged pores nor crystal deposits were observed on the
membrane surface by a microscope.
3.5. SEM Analysis. Figure 7 shows SEM images of PRX
monohydrate microcrystals prepared in pure water or in the
presence of different surfactants dissolved at 0.06% (w/w). The
microcrystals in all samples exhibited an elongated rhombohe-
dral shape. Because of high interfacial tension, the crystals
formed in Milli-Q were clumped together into flower or star-
like agglomerates (see Figure 7a). Because of steric hindrance
induced by the adsorbed surfactant molecules, the crystals
formed in the surfactant solutions were smaller and less
aggregated (Figure 7b−d). The most uniform crystals with
negligible agglomeration were formed in the presence of 0.06
wt % HPMC. Because of their uniform size, these crystals had
the highest tendency to stack together into densely packed
parallel layers. More agglomerates were formed in the presence
of P-123 and PVA, which is in good correlation with the optical
micrographs shown in Figure 4, and confirm that HPMC is the
best surfactant for stabilizing PRX monohydrate microcrystals
in the antisolvent precipitation process.
3.6. Polymorphic form Validation. The Raman spectra of
anhydrous PRX (Form I) and PRX monohydrate (Form II)
obtained by membrane crystallization are shown in Figure 8a.
The characteristic bands of polymorphic form I are at 1335
cm−1 due to symmetric R-NO2 stretching, at 1523 cm
−1 due to
asymmetric R-NO2 stretching, and in the region of 883 cm
−1,
corresponding to C−H bonds in aromatic rings. On the other
hand, PRX monohydrate showed characteristic peaks at 1007
and 1400 cm−1 regions related to C−H stretching and
symmetrical in-plane deformation of CH2, respectively.
56,57
These spectra confirm a complete transformation of Form I to
monohydrate achieved in the dispersion cell without using
elevated temperature or supercritical conditions.
The DSC curves of anhydrous PRX (Form I) and PRX
monohydrate (For II) prepared by membrane crystallization
are shown in Figure 8b. A sharp endothermic peak of
anhydrous PRX at 203 °C corresponds to its melting point.
Additional endothermic peak at 280 °C was due to the thermal
degradation of pure PRX. The DSC curve of PRX monohydrate
showed a broad endothermic peak at 150 °C corresponding to
the loss of crystal water, which is consistent with previous
studies.67,68 Dehydration usually begins at lattice defects or on
the crystal surface, where the molecules are more energetic and
then expands to the rest of the lattice with further increase in
temperature.30 The second peak at 202 °C was due to the
melting of the anhydrous form.
3.7. Comparison of Different Antisolvent Crystalliza-
tion Systems. In this section, four different antisolvent
crystallization methods were used to prepare PRX mono-
hydrate microcrystals using pure water as antisolvent. Table 1
summarizes the operating conditions used and the average size
and uniformity of the microcrystals obtained in each system.
Bulk mixing (method 1) is the simplest method of
antisolvent crystallization. In this method, pure water was
quickly poured into the feed solution without stirring or
shaking, which resulted in large crystals (d[4,3] = 86 ± 7.6 μm)
and a very broad CSD (span = 2.3) (Table 1 and Figure 9), due
to uncontrollable mixing process. Furthermore, a mixture of
prism-shaped (Form I) and needle-shaped (Form II) crystals
was formed, as shown in the optical micrographs in Figure 10.
The existence of two crystal shapes indicated that two different
polymorphs were formed, due to poor mixing and generation of
zones of different supersaturation levels. PRX precipitates in
needle form (Form II) when allowed to crystallize from an
ethanolic solution by fast cooling, while crystals in cubic form
(Form I) are obtained by slow cooling from the same
solution.69 In this case, the occurrence of needles can be
explained by rapid addition of the antisolvent.
When the feed solution was directly injected into Milli-Q
water stirred in the cell, without penetration through the
membrane (Method 2), a bimodal CSD curve was obtained, as
shown in the inset to Figure 9. The first peak at ∼30 μm was
from individual crystals, while the second shallow peak at ∼250
μm originated from agglomerates, formed due to high local
supersaturation levels near the feed injection point. The
Figure 7. SEM images of PRX monohydrate microcrystals prepared using a ringed stainless-steel membrane with a pore size of 10 μm. Antisolvent
was (a) Milli-Q water; (b) HPMC; (c) 0.06 wt % P-123; and (d) 0.06 wt % PVA. The PRX concentration in the feed solution was 25 g L−1.
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agglomerates of irregular shape are visible in the optical
micrographs in Figure 10 (Method 2).
When the feed solution was injected through the membrane
into stirred Milli-Q water (Method 3), a monomodal CSD
curve was obtained (Figure 9) due to uniform supersaturation
along the membrane surface. The microcrystals were more
uniform and less aggregated than those prepared by direct
injection (Figure 10), due to controlled addition of the feed
solution through the pores and uniform mixing at the molecular
level: since nucleation was much faster than mixing, the size
distribution and polymorphic form of the crystals were
governed by the kinetics of the mixing step.
A continuous flow system shown in Figure 1b was used in
method 4 to achieve more significant crystal growth than that
in the batch system. The residence time distribution (RTD) of
microcrystals in the stirred cell for ideal mixing is given by F(t)
= 1 − e − t/t,̅ where F(t) is the cumulative RTD function, i.e.,
the fraction of crystals exiting the cell that have spent a time t or
less in the cell and t ̅ is the mean residence time given by V/(Qaq
+ Qor), where V is the volume of the liquid in the cell. Since the
residence time of crystals in the case of ideal mixing ranges
from zero to infinity, some crystals will have much longer
residence times than others. As a result, both tiny crystals and
large aggregates can be found in the effluent stream after 1 min
of operation (Figure 10). The average size of the microcrystals
increased linearly from 38 μm after 1 min to more than 75 μm
after 8 min. The steady state was established after 8 min or 8.6t,̅
with only a minor further increase in mean crystal size between
8 and 15 min. The results indicate that the continuous flow
membrane crystallizer can be used to continuously produce
Figure 8. (a) Raman curves of anhydrous polymorphic form I and
monohydrate of PRX and (b) DSC curves of polymorphic form I and
monohydrate of PRX.
Table 1. Volume-Weighted Mean Diameter and the Span of PRX Microcrystals Prepared by Rapid Pouring (Method 1),
Dispersion Cell without Membrane (Method 2), Batch Dispersion Cell with Membrane (Method 3), and Continuous
Dispersion Cell (Method 4)a
method Vaq/Vor or Qaq/Qor stirring speed (rpm) injection rate (mL min
−1) flux (L m−2 h−1) d[4,3] (μm) span (−)
1 5 86 ± 7.6 2.3 ± 0.21
2 5 1500 18 33 ± 1.2 1.3 ± 0.06
3 5 1500 18 4000 29 ± 0.7 1.1 ± 0.04
4b 5 1500 18 1300 39 ± 1.4 1.4 ± 0.01
aThe feed solution was 15 g L−1 PRX in acetone injected at 18 mL min−1, and the antisolvent was pure water. A whole nickel membrane with a pore
size of 40 μm was used in Methods 3 and 4. Note: Each experiment was repeated at least three times. The error bars represent one standard
deviation. bSample taken after 1 min of operation.
Figure 9. Variation of the volume-weighted mean diameter of
microcrystals with time in a continuous dispersion cell (method 4).
The inset figure shows CSD curves for rapid pouring (method 1),
dispersion cell without membrane (method 2), and batch dispersion
cell with membrane (method 3). The PRX concentration in the feed
solution was 15 g L−1, antisolvent was pure water, and Vaq/Vor or Qaq/
Qor was 5. The membrane used in methods 3 and 4 was a nickel
membrane with a pore size of 40 μm. The stirring rate was zero in
method 1 and 1500 rpm in methods 2−4.
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relatively large crystals whose size can be controlled by the
mean residence time. At constant flow rate of the organic phase
through the membrane, the mean residence time in the cell can
be reduced by increasing the flow rate of the aqueous phase,
which would lead to a decrease in mean crystal size, and a
steady state would be reached more quickly.
4. CONCLUSIONS
In this study, a novel membrane antisolvent crystallization
technique has been developed and used for the preparation of
piroxicam (PRX) monohydrate microcrystals. It was shown that
PRX can precipitate in the cubic form by controlled addition of
a piroxicam/acetone solution through the membrane pores into
a well-stirred antisolvent. The size of PRX crystals was
controlled by varying the concentration of PRX in the feed
solution, antisolvent/solvent ratio, and the type and concen-
tration of stabilizer in the aqueous phase. Higher super-
saturations were achieved using the feed solution with a higher
concentration of PRX, which promoted nucleation and led to
smaller crystals. The crystals formed at an aqueous-to-organic
volume ratio of 30 were larger than those obtained at the
volume ratio between 10 and 20, due to inhibition of contact
secondary nucleation. Rapid pouring of Milli-Q water into a
PRX/acetone solution resulted in the precipitation of PRX in
both cubic and needle forms, and the generated crystals were
large and highly polydispersed, due to an uncontrolled mixing
process.
Small drug crystals are desirable in the pharmaceutical
industry to improve dissolution rate and bioavailability. The
optimum procedure for producing small and nonaggregated
PRX crystals with narrow size distribution was to inject a PRX/
acetone solution containing 25 g L−1 of PRX through a ringed
stainless-steel membrane with a pore size of 10 μm into an
aqueous 0.06 wt % HPMC solution at 1500 rpm and Qaq/Qor =
20. HPMC provided better steric stabilization of PRX crystals
against agglomeration than PVA and P-123 surfactants, due to
hydrogen bonding between HPMC and water or PRX
molecules. A complete transformation of the anhydrous form
of PRX into monohydrate was confirmed by Raman spectros-
copy and DSC.
A continuous production of large PRX monohydrate crystals
with a volume-weighted mean diameter above 75 μm was
Figure 10. Optical micrographs of PRX monohydrate microcrystals prepared by different methods: (1) Rapid pouring; (2) dispersion cell without
membrane; (3) batch dispersion cell with membrane; (4) continuous dispersion cell after 1 min of operation. Feed solution: 15 g L−1 PRX in
acetone, Vaq/Vor = 5 for methods 1−3 and Qaq/Qor = 5 for method 4. Membrane: 40-μm Ni membrane in methods 3 and 4. No surfactant was
added.
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achieved in a continuous dispersion cell. The size distribution
of the formed crystals was broad, due to a wide range of
residence times of crystal seeds in the crystallizer. More
uniform crystal size distribution could be achieved using
membrane crystallizers with more uniform residence time
distribution, such as tubular cross-flow membrane modules, due
to unidirectional flow of an antisolvent through the membrane
tube.
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